Acknowledging and addressing real-world challenges to treating immune-related adverse events by Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara

Get full text

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

Get full text

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer by Mitchell S. von Itzstein, MD, Jialiang Liu, PhD, Hong Mu-Mosley, PhD, Farjana Fattah, PhD, Jason Y. Park, MD, PhD, Jeffrey A. SoRelle, MD, J. David Farrar, PhD, Mary E. Gwin, MD, David Hsiehchen, MD, Yvonne Gloria-McCutchen, Edward K. Wakeland, PhD, Suzanne Cole, MD, Sheena Bhalla, MD, Radhika Kainthla, MD, Igor Puzanov, MD, MSCI, Benjamin Switzer, DO, MHSA, MS, Gregory A. Daniels, MD, PhD, Yousef Zakharia, MD, Montaser Shaheen, MD, Jianjun Zhang, MD, PhD, Yang Xie, PhD, David E. Gerber, MD

Get full text